IMAAVY® (nipocalimab-aahu) shows over two years of sustained disease control in a broad population with generalized myasthenia gravis (gMG)

Johnson & Johnson (NYSE: JNJ) today announced new data from the Phase 3 Vivacity-MG3 study and ongoing open label extension (OLE) in a broad population of antibody-positive (including anti-AChR+a and ...
Yahoo Finance

FDA Approves Johnson & Johnson’s IMAAVYTM (nipocalimab-aahu) a New Treatment for Myasthenia Gravis (MG), Offering Hope for Families

New York, April 30, 2025 (GLOBE NEWSWIRE) -- Muscular Dystrophy Association (MDA) applauds the U.S. Food and Drug Administration (FDA) approval of IMAAVY TM (nipocalimab-aahu) for the treatment of ...
Seeking Alpha

IMAAVY™ (nipocalimab-aahu) showed greater sustained disease control versus approved FcRn blockers for generalized myasthenia gravis (gMG) at multiple timepoints over 24 weeks ...

The ITC compared all published Phase 3 data of these treatments, leveraging longitudinal results, and findings reinforce the importance of consistent, sustained disease control in managing a chronic ...
Healio

nipocalimab-aahu

Nipocalimab is used to treat a certain muscle condition (generalized myasthenia gravis). It may help to improve symptoms of muscle weakness. Read the Patient Information Leaflet if available from your ...
Mena FN

FDA Approves Johnson & Johnson’S IMAAVYTM (Nipocalimab-Aahu) A New Treatment For Myasthenia Gravis (MG), Offering Hope For Families

(MENAFN- GlobeNewsWire - Nasdaq) First and only FcRn blocker approved in anti-AChR and anti-MuSK antibody positive adults and pediatric gMG patients aged 12 and older. New York, April 30, 2025 (GLOBE ...